
AgeX Therapeutics AGE
AgeX Therapeutics ROCE Ratio | AGE
Annual ROCE Ratio AgeX Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -709.03 | -379.6 | 10.85 | 103.58 | 137.49 | 876.74 | -302.99 | -136.62 | - | 77.56 | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 876.74 | -709.03 | -35.78 |
Quarterly ROCE Ratio AgeX Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -435.67 | -493.79 | -463.02 | -596.8 | -540.92 | -277.16 | 27.11 | 169.39 | 295.89 | 212.98 | 15.9 | 11.08 | 18.44 | 36.75 | 57.46 | 81.57 | 107.16 | 124.5 | 180.81 | 437.42 | 567.8 | 895.87 | -4566.72 | -4048.98 | -4277.01 | -4707.36 | 629.34 | -313.55 | -277.6 | -244.11 | -246.67 | -105.91 | -29.57 | -28.66 | -47.68 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 895.87 | -4707.36 | -509.48 |
ROCE Ratio of other stocks in the Biotechnology industry
| Issuer | ROCE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ADiTx Therapeutics
ADTX
|
-328.78 | - | - | $ 374 | ||
|
Aeterna Zentaris
AEZS
|
-76.42 | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-29.14 | - | - | $ 1.01 B | ||
|
AIkido Pharma
AIKI
|
-80.33 | - | 1.93 % | $ 17.4 M | ||
|
Aileron Therapeutics
ALRN
|
-281.63 | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
-41.2 | - | 4.14 % | $ 49.1 M | ||
|
Apellis Pharmaceuticals
APLS
|
7.37 | - | - | $ 5.18 B | ||
|
Athira Pharma
ATHA
|
-229.05 | - | - | $ 269 M | ||
|
AVROBIO
AVRO
|
-33.43 | - | 1083.1 % | $ 745 M | ||
|
AstraZeneca PLC
AZN
|
16.47 | - | - | $ 96.9 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
99.68 | - | -2.5 % | $ 5.88 M | ||
|
BeiGene, Ltd.
BGNE
|
7.03 | - | 0.49 % | $ 251 B | ||
|
EyePoint Pharmaceuticals
EYPT
|
-74.45 | $ 0.23 | -12.11 % | $ 16.8 K | ||
|
Bio-Path Holdings
BPTH
|
-2039.46 | - | - | $ 100 K | ||
|
Cara Therapeutics
CARA
|
-127.18 | - | -3.03 % | $ 260 M | ||
|
ChromaDex Corporation
CDXC
|
18.82 | - | -0.88 % | $ 598 M | ||
|
Caladrius Biosciences
CLBS
|
-121.99 | - | -16.75 % | $ 25.8 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-5.84 | - | -5.98 % | $ 34.1 M | ||
|
Diffusion Pharmaceuticals
DFFN
|
-155.27 | - | 11.68 % | $ 8.97 M | ||
|
Eloxx Pharmaceuticals
ELOX
|
50.04 | - | -5.68 % | $ 8.28 M | ||
|
Enochian Biosciences
ENOB
|
96.98 | - | - | $ 40.5 M | ||
|
Esperion Therapeutics
ESPR
|
-19.96 | - | - | $ 661 M | ||
|
Evofem Biosciences
EVFM
|
-4.86 | - | 7.55 % | $ 38.1 M | ||
|
Eyenovia
EYEN
|
-95.23 | - | 49.81 % | $ 13.2 M | ||
|
FibroGen
FGEN
|
-82.19 | - | - | $ 889 M | ||
|
Homology Medicines
FIXX
|
33.52 | - | 0.77 % | $ 53.4 M | ||
|
Amicus Therapeutics
FOLD
|
11.96 | - | - | $ 4.47 B | ||
|
Frequency Therapeutics
FREQ
|
-119.97 | - | - | $ 528 M | ||
|
Galecto
GLTO
|
-87.69 | - | - | $ 762 M | ||
|
GlycoMimetics
GLYC
|
-74.74 | - | 9357.83 % | $ 1.01 B | ||
|
Graybug Vision
GRAY
|
-235.71 | - | -11.23 % | $ 9.65 M | ||
|
Galera Therapeutics
GRTX
|
-63.97 | - | -32.59 % | $ 7.61 M | ||
|
Happiness Biotech Group Limited
HAPP
|
-44.94 | - | 1.35 % | $ 17.8 M | ||
|
Novavax
NVAX
|
63.19 | $ 7.47 | -3.24 % | $ 1.21 B | ||
|
Hepion Pharmaceuticals
HEPA
|
-150.28 | - | -18.79 % | $ 39.3 K | ||
|
Hoth Therapeutics
HOTH
|
-200.97 | - | - | $ 18.8 M | ||
|
IMARA
IMRA
|
-26.04 | - | 15.96 % | $ 663 M | ||
|
KalVista Pharmaceuticals
KALV
|
-104.22 | - | - | $ 1.45 B | ||
|
KemPharm
KMPH
|
-25.64 | - | -0.34 % | $ 200 M | ||
|
Kezar Life Sciences
KZR
|
-84.35 | - | - | $ 53.3 M | ||
|
Lixte Biotechnology Holdings
LIXT
|
-50.56 | - | - | $ 63.4 M | ||
|
Magenta Therapeutics
MGTA
|
-35.57 | - | -7.74 % | $ 41.6 M | ||
|
NovaBay Pharmaceuticals
NBY
|
-111.88 | - | - | $ 11.3 M | ||
|
NeuroBo Pharmaceuticals
NRBO
|
-250.37 | - | 0.43 % | $ 12 M | ||
|
OncoCyte Corporation
OCX
|
-373.69 | - | 17.22 % | $ 355 K | ||
|
Onconova Therapeutics
ONTX
|
3379.02 | - | -0.47 % | $ 21 M | ||
|
Opthea Limited
OPT
|
77.47 | - | - | $ 1.2 B | ||
|
Verastem
VSTM
|
-97.68 | $ 6.33 | -7.8 % | $ 439 M | ||
|
BiomX
PHGE
|
6957.38 | $ 1.85 | 14.2 % | $ 3.02 M |